Tissue-targeting autoantibodies as a driver of long COVID

One implication of the recent Yale study linking autoantibody production to the development of long COVID is that treatment with therapies directed at B cells or antibody clearance might prove useful in preventing the condition.

But caution would need to be taken to avoid impairing antibody-mediated antiviral responses during acute infection study co-leader Aaron Ring, an assistant professor of immunobiology at Yale University, told BioCentury. “We imagine that timing will be absolutely critical.”...